Hexarelin

human trialThe mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng·ml−1 after 0, 0.5, 1 and 2 μg·kg−1, respectively²

human trialThe corresponding Emaxs were 55.1 ng·ml−1 and 3936 ng·min·ml−1, thus indicating that the effect after the 2 μg·kg−1 dose is very close to the maximal response²

human trialIntravenous administration of hexarelin in man produces a substantial and dose-dependent increase of growth hormone plasma concentrations²

human trialMean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng/ml after 0, 0.5, 1 and 2 micrograms/kg hexarelin respectively³

human trialThe corresponding Emax values were 55.1 ng/ml and 3936 ng·min·ml−1, indicating that the effect after the 2 micrograms/kg dose is very close to the maximal response³

human trialintravenous administration of hexarelin in man produces a substantial and dose-dependent increase of growth hormone⁴

human trialPlasma growth hormone concentrations increased dose-dependently after injection of hexarelin⁵

human trialMean peak plasma growth hormone concentrations (Cmax) were 3.9 ng/ml after 0 micrograms/kg (placebo)⁵

human trialMean peak plasma growth hormone concentrations (Cmax) were 26.9 ng/ml after 0.5 micrograms/kg hexarelin⁵

human trialMean peak plasma growth hormone concentrations (Cmax) were 52.3 ng/ml after 1 microgram/kg hexarelin⁵

human trialMean peak plasma growth hormone concentrations (Cmax) were 55.0 ng/ml after 2 micrograms/kg hexarelin⁵

human trialThe effect after 2 micrograms/kg dose is very close to the maximal response⁵

human trialHexarelin is a powerful stimulus of GH secretion in pubertal children and in adults⁶

human trialHexarelin is not a powerful stimulus of GH secretion in prepubertal children and in elderly subjects⁶

human trialIn pubertal children, the GH response to Hexarelin was higher than that to ARG + GHRH but this difference did not attain statistical significance⁶

human trialIn young adults, the GH response to Hexarelin was similar to that to ARG + GHRH⁶

human trialIn elderly subjects, the GH response to Hexarelin was higher than that to GHRH alone but lower than that to ARG + GHRH⁶

human trialAge-related variations in the GH response to GHRPs probably limit their reliability for the evaluation of GH releasable pool in prepubertal children and elderly subjects⁶

human trialHexarelin at 1 microg/kg i.v. produced Cmax of 26.8+/-10.5 ng/ml in familial short stature subjects⁹

human trialHexarelin at 1 microg/kg i.v. produced AUC of 1448+/-514 ng/min x ml in familial short stature subjects⁹

human trialHexarelin at 2 microg/kg i.v. produced Cmax of 37.7+/-16 ng/ml in familial short stature subjects⁹

human trialHexarelin at 2 microg/kg i.v. produced AUC of 1979+/-888 ng/min x ml in familial short stature subjects⁹

human trialHexarelin did not show more specificity than GHRH+pyridostigmine and arginine plus estrogen⁹

human trialSpecificity was 62% for hexarelin 1 microg/kg and 75% for hexarelin 2 microg/kg⁹

human trialHexarelin, but not rhGH, significantly increased cortisol levels¹⁰

human trialAldosterone and catecholamine levels did not change with hexarelin or rhGH administration¹⁰

human trialHexarelin increased left ventricular ejection fraction (LVEF) from 64.0±1.5% to 70.7±3.0% (p<0.03)¹⁰

human trialHexarelin did not significantly change mean blood pressure (92.8±4.7 vs 92.4±3.2 mmHg)¹⁰

human trialHexarelin did not significantly change heart rate (63.1±2.1 vs 67.0±2.9 bpm)¹⁰

human trialLVEF significantly raised at 15 min, peaked at 30 min and lasted up to 60 min after hexarelin¹⁰

human trialHexarelin significantly increased ACTH and cortisol release¹¹

human trialHexarelin also caused significant GH and PRL release¹¹

human trialHexarelin caused an acute small increment in appetite¹¹

human trialThe effect of hexarelin on the HPA axis was augmented by the addition of CRH in a dose that on its own produces maximal stimulation¹¹

human trialHexarelin effects were not influenced by the addition of desmopressin¹¹

human trialHexarelin produces the strongest GH peaks of any GHRP in comparative studies¹³

human trialHexarelin produces peak GH 20–30% greater than GHRP-2¹³

human trialIncreases of 10-25 fold above baseline levels in healthy subjects¹³

human trialIn seven healthy male volunteers, acute intravenous injection of hexarelin enhanced left ventricle ejection fraction (LVEF) (70.7 ± 3.0% vs. 64.0 ± 1.5%, P < 0.03) without impacting mean blood pressure or heart rate¹⁴

human trialIn seven healthy male volunteers, LVEF began to rise sharply 15 minutes after hexarelin injection, reaching maximum at 30 minutes, with effects continuing for up to 60 minutes¹⁴

human trialIn 24 male patients with coronary artery disease undergoing bypass surgery, intravenous infusion of hexarelin (2 µg/kg) caused quick rise in LVEF, cardiac output, and cardiac index, with concurrent decrease in wedge pressure¹⁴

human trialIn the landmark 1994 clinical study by Ghigo et al., intravenous hexarelin at 1-2 μg/kg elicited robust GH peaks in healthy volunteers via multiple routes of administration including intravenous, subcutaneous, intranasal, and oral²⁵

human studyGhrelin administration can improve cardiac function in rats and patients with chronic heart failure, indicated by increased left ventricle ejection fraction (LVEF), cardiac output, and exercise capacity⁷

human studyAcute intravenous administration of hexarelin had a short-lasting, positive inotropic effect in seven male volunteers⁷

human studyHexarelin administration increased LVEF (70.7 ± 3.0% vs. 64.0 ± 1.5%, P < 0.03) without affecting mean blood pressure and heart rate⁷

human studyLVEF was significantly increased after 15 min and peaked at 30 min, and the effect lasted for up to 60 min after administration⁷

human studyGHSs might improve growth velocity in children⁸

human studyGHSs might stimulate appetite⁸

human studyGHSs might improve lean mass in wasting states and in obese individuals⁸

human studyGHSs might decrease bone turnover⁸

human studyGHSs might increase fat-free mass⁸

human studyGHSs might improve sleep⁸

human studyGH-releasing activity of GHRPs is marked and dose-related after intravenous, subcutaneous, intranasal and even oral administration¹²

human studyProlonged administration of GHRPs increases IGF-1 levels both in animals and in humans¹²

human studyThe GH-releasing effect of GHRPs does not depend on sex but undergoes age-related variations¹²

human studyGH-releasing activity increases from birth to puberty, persists at a similar level in adulthood and decreases thereafter¹²

human studyBy the sixth decade of life, the activity of GHRPs is reduced but it is still marked and higher than that of GHRH¹²

human studyGHRPs maintain their GH-releasing effect in somatotrope hypersecretory states such as in acromegaly, anorexia nervosa and hyperthyroidism¹²

human studyReduced GH responses after GHRP administration have been reported in idiopathic GH deficiency, idiopathic short stature, obesity and hypothyroidism¹²

human studyIn patients with pituitary stalk disconnection or Cushing's syndrome the somatotrope responsiveness to GHRPs is almost absent¹²

human studyIn short children an increase in height velocity has been reported during chronic GHRP treatment¹²

human studyClinical studies document improved cardiac output, enhanced left ventricular ejection fraction, and reduced markers of cardiac stress following Hexarelin administration¹³

human studyHexarelin shows a positive inotropic effect in normal subjects as well as in patients with GH deficiency²⁰

human studyThe synthetic growth hormone releasing peptides (GHRPs) GHRP-6 and hexarelin elicit in obese patients GH responses greater than those evoked by GHRH, but still lower than those observed in lean subjects.²¹

human studyThe GH-releasing effect of GHRPs is the same in both sexes, but undergoes age-related variations, increasing from birth to puberty and decreasing in aging²³

human studyGHRPs maintain their GH-releasing effect in somatotrope hypersecretory states such as acromegaly, anorexia nervosa, and hyperthyroidism²³

human studyIn patients with pituitary stalk disconnection and in Cushing's syndrome the somatotrope responsiveness to GHRPs is almost absent²³

human studyCombined administration of low-dose hexarelin with GHRH produces synergistic GH release far exceeding the response to either agent alone²⁵

animalIn rodents with acute myocardial infarction, ghrelin administration prevented malignant arrhythmias and reduced mortality in the acute phase, while improving left ventricle dysfunction and attenuating cardiac remodeling in the subacute phase⁷

animalHexarelin treatment reduces infarct size by 40-60% in myocardial ischemia-reperfusion injury models¹³

animalHexarelin improves left ventricular function parameters and decreases cardiac enzyme release in myocardial injury models¹³

animalStudies in post-infarction models demonstrate reduced interstitial and perivascular fibrosis in Hexarelin-treated hearts compared to controls¹³

animalHexarelin exhibits significant protection against organ injury in models of ischemia/reperfusion (I/R)-induced injury (IRI)¹⁶

animalPretreatment with Hexarelin exhibits a protective effect by mitigating post-ischemic kidney pathological changes, improving renal function, and inhibiting apoptosis in rats subjected to I/R¹⁶

animalHexarelin administration decreased infrarenal aorta diameter in a mouse model of elastase-induced abdominal aortic aneurysm¹⁷

animalHexarelin attenuated abdominal aortic aneurysm development by inhibiting SMC phenotype switch and NF-κB signaling mediated inflammatory response¹⁷

animalGHRP hexarelin regulates PPARγ downstream actions with benefits on atherosclerosis¹⁸

animalHexarelin injected into the paraventricular nucleus of the hypothalamus did not increase spontaneous penile erections in male rats¹⁹

animalHexarelin protects from ischemia-induced myocardial damage in aged and GH deficient rats²⁰

animalGH peak response to acute hexarelin initially increased with maximum at 3rd week, then decreased to basal values or less at 6th week²²

animalGH peak response to acute GHRH initially increased with maximum at 3rd week, then decreased to basal values at 6th week²²

animalAcute feeding response to hexarelin was abolished at 3rd week and returned to normal at 6th week²²

in vitroHexarelin reduced cell apoptosis in post-H/R HK-2 cells in vitro¹⁶

expert opinionHexarelin is protective in cardiovascular diseases such as myocardial infarction and atherosclerosis¹⁷

expert opinionAmong the growth hormone-releasing peptides (GHRPs), hexarelin produces the most potent acute GH release in humans²⁵

human trialThe acute administration of hexarelin exerts a short-lasting, positive inotropic effect¹⁰

human trialThe inotropic effect of hexarelin seems GH-independent and might be mediated by specific GHS myocardial receptors¹⁰

human trialHexarelin stimulates the hypothalamo-pituitary-adrenal (HPA) axis via central mechanisms probably involving CRH or arginine vasopressin (AVP)¹¹

human trialThe effect of hexarelin on the HPA axis does not involve CRH, but may occur through the stimulation of AVP release¹¹

human trialThe effect of GHSs on the HPA axis involve at least in part the stimulation of AVP release¹¹

human trialGH secretagogues act via specific receptors in the hypothalamus and the pituitary gland to release GH¹¹

human studyCD36 is a specific cardiac receptor for hexarelin that mediates its cardioprotective effects⁷

human studyGH secretagogues promote pulsatile release of GH that is subject to negative feedback and can prevent supra-therapeutic levels of GH and their sequelae⁸

human studyGHRPs including Hexarelin have potent stimulatory effects on somatotrope secretion in animals and humans¹²

human studyThe GH-releasing activity of GHRPs is synergistic with that of GHRH¹²

human studyGH-releasing activity is not affected by opioid receptor antagonists, such as naloxone¹²

human studyHighest GHRP receptor binding levels in human cardiovascular system were detected in ventricles, followed by atria, aorta, coronaries, carotid, endocardium and vena cava²⁰

human studyHexarelin demonstrates direct cardioprotective effects independent of GH release, mediated through binding to the CD36 scavenger receptor on cardiomyocytes²⁵

human studyPapotti et al. (2000) demonstrated that GHS binding sites were present at highest density in human myocardium, exceeding binding in all other peripheral tissues examined²⁵

animalHexarelin shows cardioprotective effects through the CD36 receptor, independent of GH¹³

animalHexarelin interacts with cardiac-specific receptors, including CD36, which may mediate cardiovascular effects independently of GH release¹³

animalHexarelin's interaction with CD36 scavenger receptor on cardiac myocytes activates PI3K/Akt pathway and ERK1/2 phosphorylation¹³

animalHexarelin may possess anti-fibrotic properties in cardiac tissue through modulation of fibroblast activity and extracellular matrix remodeling pathways¹³

animalAnti-fibrotic effects may be mediated through suppression of transforming growth factor beta (TGF-β) signaling¹³

animalHexarelin induced inotropic effects in rat papillary muscle that were concentration- and time-dependent¹⁴

animalHexarelin increased amplitude of intracellular Ca2+ transients and L-type Ca2+ current in newly isolated adult Wistar rat ventricular myocytes through a protein kinase C signaling cascade¹⁴

animalHexarelin treatment dramatically reduced angiotensin II-induced apoptosis and DNA fragmentation in newborn rat cardiomyocytes while increasing myocyte viability¹⁴

animalHexarelin (1 µmol/L) significantly decreased the size of infarcts in hearts after 30 minutes of ischemia and 120 minutes of reperfusion according to triphenyltetrazolium chloride staining¹⁴

animalThe protective effect of hexarelin against ischemia-reperfusion injury was partially eliminated by protein kinase C inhibitor chelerythrine¹⁴

animalHexarelin's protective effect is achieved through downregulation of conventional apoptosis-related genes, such as Caspase-3, Bax and Bad, and upregulation of the anti-apoptotic protein Bcl-2¹⁶

animalHexarelin significantly suppresses MDM2 and p53 in both in vivo and in vitro experiments of I/R-induced AKI¹⁶

animalHexarelin improved elastin degradation in hexarelin-treated group compared to control¹⁷

animalHexarelin rescued smooth muscle cell contractile phenotype with increased α-SMA and decreased MMP2¹⁷

animalHexarelin inhibited inflammatory cell infiltration¹⁷

animalHexarelin inhibited NLRP3 inflammasome activation and IL-18 production¹⁷

animalHexarelin suppressed NF-κB signaling pathway which is a key initiator of inflammatory response¹⁷

animalGHRP hexarelin regulates PPARγ downstream actions with benefits on hepatic cholesterol biosynthesis¹⁸

animalGHRP hexarelin regulates PPARγ downstream actions with benefits on fat mitochondrial biogenesis¹⁸

animalEP 60761 and EP 50885, but not hexarelin, increased dose-dependently the number of spontaneous penile erections when injected into the paraventricular nucleus¹⁹

animalEP 60761-induced penile erection was prevented by oxytocin receptor antagonist given intracerebroventricularly¹⁹

animalEP 60761-induced penile erection was prevented by NO inhibitor L-NAME given into paraventricular nucleus or intracerebroventricularly¹⁹

animalEP 60761-induced penile erection was prevented by N-type Ca2+ channel blocker omega-conotoxin-GVIA¹⁹

animalEP 60761-induced penile erection was prevented by morphine but not by dopamine receptor antagonist or NMDA receptor antagonist¹⁹

animalEP 60761 and EP 50885 induced penile erection by increasing central oxytocin transmission through activation of NO synthase in oxytocinergic neurons in the paraventricular nucleus¹⁹

animalHexarelin initially primed the pituitary to acute administration of further hexarelin or GHRH, followed by downregulation of GH response to hexarelin²²

animalResponse to GHRH was preserved despite hexarelin downregulation²²

animalDifferent timing of neuroendocrine versus behavioural response to hexarelin suggests existence of different subtypes of central nervous system GH-releasing peptide receptors²²

animalHexarelin is a hexapeptide growth hormone-releasing peptide (GHRP) that has been shown to be effective at releasing GH in animals and humans²³

animalThe GH-releasing activity of GHRPs is synergistic with that of GHRH²³

animalGH-releasing activity of GHRPs is not affected by opioid receptor antagonists²³

animalGH-releasing activity of GHRPs is blunted by inhibitory influences such as neurotransmitters, glucose, free fatty acids, glucocorticoids, rhGH, and exogenous somatostatin²³

animalThe short biological window reflects rapid enzymatic degradation in plasma and contributes to the transient nature of the GH pulse it produces²⁴

animalPrimary clearance route is enzymatic (plasma peptidases) plus renal, inferred from analog studies²⁴

animalHexarelin is subject to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) and other plasma enzymes²⁴

animalThe cardioprotective effects of hexarelin were absent in hearts from CD36-null mice and spontaneously hypertensive rats genetically deficient in CD36²⁵

in vitroHexarelin's cardiac action is mediated in part by GHSR 1a and largely by activation of the CD36 receptor in isolated working hearts⁷

in vitroHexarelin therapy increased lifespan of H9c2 cardiomyocytes and endothelial cells and prevented doxorubicin-induced apoptosis¹⁴

in vitroAlexamorelin is a synthetic peptide and growth hormone secretagogue (GHS) with potential performance-enhancing properties¹⁵

in vitroGrowth hormone releasing peptides (GHRP) are potent inducers of PPARγ through activation of the scavenger receptor CD36¹⁸

in vitroGH-releasing peptides exhibit strong, dose-dependent and reproducible GH-releasing activity²⁰

in vitroGH-releasing peptides have significant PRL- and ACTH/cortisol-releasing effects²⁰

in vitroGHRP receptors are identified in the pituitary gland, hypothalamus and various extra-hypothalamic brain regions²⁰

in vitroGHRP receptors are present in peripheral tissues such as heart, adrenal, ovary, testis, lung and skeletal muscle with density significantly higher than in the hypothalamo-pituitary system²⁰

in vitroHexarelin showed anti-apoptotic activity in H9c2 myocytes²⁰

in vitroGHRPs possess direct GH-independent cardiotropic effects²⁰

in vitroGHRPs act via specific receptors present at either the pituitary or the hypothalamic level²³

in vitroThe GHRP receptor has been cloned and does not show sequence homology with other G-protein-coupled receptors known so far²³

in vitroBodart et al. (2002) identified CD36, an 88 kDa multifunctional glycoprotein expressed on cardiomyocytes and microvascular endothelial cells, as the specific cardiac receptor responsible for the cardiovascular effects of hexarelin²⁵

expert opinionHexarelin is a synthetic growth hormone-releasing peptide that can bind to and activate the growth hormone secretagogue receptor (GHSR) in the brain similar to its natural analog ghrelin⁷

expert opinionGHSR is peripherally distributed in the heart and blood vessels, suggesting hexarelin might have direct cardiovascular actions beyond growth hormone release and neuroendocrine effects⁷

expert opinionGHRP receptor does not show sequence homology with other G-protein-coupled receptors known so far¹²

expert opinionHexarelin lacks protective modifications such as PEGylation or albumin-binding sequences used in longer-acting pharmaceutical compounds²⁴

expert opinionHexarelin was designed as a structural modification of GHRP-6, incorporating a D-2-methyltryptophan substitution that confers enhanced metabolic stability and increased GH-releasing potency²⁵

expert opinionHexarelin binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein coupled receptor expressed primarily on somatotroph cells of the anterior pituitary²⁵

expert opinionHexarelin also stimulates GH release at the hypothalamic level by promoting GHRH neuron activity and by antagonizing somatostatin tone²⁵

expert opinionHexarelin is a synthetic growth hormone-releasing peptide that can bind to and activate the growth hormone secretagogue receptor (GHSR) in the brain similar to its natural analog ghrelin²⁶

expert opinionGHSR is distributed peripherally in the heart and blood vessels, suggesting hexarelin might have direct cardiovascular actions beyond growth hormone release and neuroendocrine effects²⁶

expert opinionCD36 is a non-GHSR cardiac receptor for hexarelin that mediates its cardioprotective effects²⁶

expert opinionHexarelin mechanisms are relevant to ageing pathways involving growth hormone axis and insulin-like growth factor (GH/IGF)²⁷

theoreticalHexarelin is a synthetic hexapeptide growth hormone secretagogue featuring a D-2-methyltryptophan substitution that increases GHSR-1a binding affinity and proteolytic resistance¹³

theoreticalHexarelin is a hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) that functions via particular receptors in the pituitary and hypothalamus regions to induce growth hormone production in both animals and humans¹⁴

theoreticalHexarelin exhibits considerable prolactin and adrenocorticotropin (ACTH) cortisol-releasing action¹⁴

theoreticalAlexamorelin mimics the natural peptide hormone ghrelin by binding to the GHS type 1a receptor (GHS-R1a) in the pituitary gland, thereby promoting endogenous growth hormone release¹⁵

theoreticalMolecular docking revealed a strong binding affinity between Hexarelin and MDM2¹⁶

theoreticalHexarelin's anti-apoptosis effect is at least partially through its interaction with MDM2, a well-known negative regulator of apoptosis-related protein p53¹⁶

theoreticalHexarelin is a synthetic growth hormone-releasing peptide¹⁷

theoreticalThe GHRP-CD36-PPARγ pathway controls various tissue metabolic functions¹⁸

theoreticalGHRPs probably have a dual site of action on both the pituitary and the hypothalamus, possibly involving regulatory factors in addition to GHRH and somatostatin²³

theoreticalReceptor activation triggers phospholipase C signaling, inositol 1,4,5-trisphosphate production, and subsequent increases in intracellular calcium, leading to GH exocytosis²⁵

theoreticalThe benefits of the injection would peak then diminish, leaving the test subject at baseline²⁸

theoreticalHexarelin was screened against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) and its cofactors (nsp7 and nsp8) in an in silico drug repurposing study of 7922 FDA approved molecules³⁰

human trialIn humans, following hexarelin injection at doses of 0.5, 1, and 2 μg·kg−1, plasma growth hormone concentrations rose dose-dependently, reaching maximum at 30 minutes after injection and falling to baseline levels within 240 minutes¹⁴

human trialIn humans, hexarelin has a half-life of around 55 minutes¹⁴

human studyThe effect of GHRPs is reproducible and undergoes partial desensitization, more during continuous infusion, less during intermittent administration¹²

animalIn dogs, hexarelin administered intravenously has a long terminal half-life of 120 minutes, fractional plasma clearance of 4.28 ml/min/kg, and volume of distribution at steady state of 387.7 ml/kg¹⁴

animalIn dogs, after SC injection of hexarelin, clearance ranged from 3.93-5.17 ml/min/kg and volume of distribution ranged from 316-544 ml/kg¹⁴

animalIn rats, volume of distribution at steady state was 744 +/- 81 ml/kg, systemic clearance was 7.6 +/- 0.7 ml/min/kg, and half-life was 75.9 +/- 9.3 minutes after intravenous injection¹⁴

animalIn rats, when hexarelin is administered subcutaneously, bioavailability is 64%¹⁴

animalIn rats, the duodenum, kidney, and liver had the greatest quantities of radioactivity after hexarelin administration¹⁴

animalThe marked GH-releasing activity of GHRPs is reproducible and dose-related after intravenous, subcutaneous, intranasal, and even oral administration²³

animalHexarelin has a relatively short plasma half-life estimated at approximately 30 to 60 minutes in most animal models²⁴

animalTime to peak GH (Tmax) is 15–30 minutes post-injection with SC administration in rodent models²⁴

animalGH response duration is 60–90 minutes post-peak before returning to baseline²⁴

in vitroN-Acetylation was identified as the primary transformation of alexamorelin, with the highest probability score (98%), and occurring either at the C-terminal Ala or the N-terminal Lys¹⁵

in vitroOther predicted transformations of alexamorelin included N-oxidation, hydroxylation, amide hydrolysis, oxidative deamination, and phase II N-glucuronidation, with probability scores below 40%¹⁵

in vitroAfter 3 h of incubation with hepatocytes, only one metabolite (known as examorelin or hexarelin) was detected, resulting from the C-terminal cleavage of the Ala amino acid; this metabolic reaction is mediated by a carboxypeptidase¹⁵

in vitroThe alexamorelin signal decreased approximately 150-fold after 3 h, indicating significant hepatic metabolism¹⁵

expert opinionHexarelin is a chemically stable and potent synthetic hexapeptide that can be administered orally⁷

theoreticalHexarelin has a relatively short half-life of about one hour²⁸

theoreticalHexarelin exhibits a relatively brief half-life (approximately 30-40 minutes)²⁹

human studyApproximately 40% maximal cortisol increase at 0.5 μg/kg IV²⁵

human studyApproximately 80% increase in prolactin from baseline at standard doses²⁵

expert opinionLyophilized hexarelin stored at proper temperatures can remain intact for extended periods²⁴

expert opinionReconstituted solutions require careful cold-chain management to preserve activity²⁴

expert opinionUnlike ipamorelin, hexarelin activates multiple neuroendocrine pathways at GH-releasing doses including ACTH and cortisol stimulation²⁵

theoreticalExamorelin (hexarelin) is a commercially available GHS secretagogue¹⁵

theoreticalA potential role in the treatment of short stature, aging, catabolic states, and dilated cardiomyopathy has been envisaged²³